Micrologix acquires clinical-stage hepatitis C drug candidate
04-Feb-2004 -
VANCOUVER - Micrologix Biotech Inc., a developer of anti-infective drugs, has acquired the global rights to celgosivir (to be designated as "MBI-3253"), a Phase I/II clinical-stage compound, from Virogen Ltd. (UK). Celgosivir, which has been in over 600 subjects in human clinical studies to date, ...
anti-infectives
clinical trials
hepatitis C
+4